Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President

AUSTIN, Texas, Aug. 02, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew, PhD, was promoted to President of Lumos Pharma effective August 1, 2021 as part of the Company’s planned succession.

“I am excited to announce the promotion of John to President as part of the Lumos Pharma succession planning undergone by the Company and our Board of Directors,” commented Rick Hawkins, Chairman and CEO of Lumos Pharma. “I have worked with John for nearly ten years at both Lumos and, prior to that, in a collaboration during his tenure at the NIH. Our interactions over this period and John’s contributions as COO and Chief Scientific Officer at Lumos Pharma support our decision to turn over more responsibility to him. John has proven to be an outstanding leader, and this promotion is a testament to that and to his unwavering commitment to the Company”

John McKew, PhD has nearly 30 years of experience developing novel therapeutics during which he successfully advanced multiple therapies through preclinical and into clinical development. At Lumos Pharma, Dr. McKew has served as Chief Operating Officer since April 2020 and as Chief Scientific Officer since he joined the company in 2016. In these positions, he has helped identify clinical and commercial opportunities for Lumos Pharma and has played a key role in the development and implementation of the Company’s clinical and corporate strategy to support a successful path to commercialization and value creation.

Prior to Lumos Pharma, Dr. McKew served as Vice President of Research at aTyr Pharma where he led a research team discovering and advancing protein-based therapeutics for rare diseases. He has also served as Acting Scientific Director for the National Center for Advancing Translational Science (NCATS) intramural group, a part of the National Institute of Health (NIH). At NCATS, his lab’s work on rare diseases and public/private partnerships led to the collaborative advancement of several therapeutic candidates currently being commercialized by pharmaceutical companies. Prior to his position at the NIH, Dr. McKew held a Director level position at Wyeth Research, after beginning his career at Genetics Institute, Inc., before the two companies merged.

Beyond his work with Lumos Pharma, Dr. McKew is currently an Adjunct Professor at the Boston University School of Medicine and has previously served as the Chair Elect, Chair, and Immediate Past Chair of the American Chemical Society’s Northeastern section. Dr. McKew also serves on multiple translational review panels at the NIH and other funding agencies. He has over 70 peer-reviewed publications and granted patents. Dr. McKew graduated from State University of New York at Stony Brook with B.S. degrees in Chemistry and Biochemistry He completed his Ph.D. in Organic Chemistry at University of California, Davis and held post-doctoral research positions at the University of Geneva and Firmenich, SA.

“I am honored to accept the position of President of Lumos Pharma,” John McKew stated, “and look forward to continuing my work with Rick and the entire team to advance our current LUM-201 program for children with growth hormone deficiency and execute on our clinical and corporate goals.”

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowtH210 Trial, and a PK/PD trial, the OraGrowtH212 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Lumos Pharma, Inc. (the “Company”) that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “forecast,” “projected,” “guidance,” “upcoming,” “will,” “would,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” “imminent,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, anticipated market reception to our treatment regimen for PGHD and other indications, plans related to initiation and execution of clinical trials, and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that the Company makes due to a number of important factors, including the effects of pandemics or other widespread health problems, the outcome of our future interactions with regulatory authorities, the ability to obtain the necessary patient enrollment for our product candidate in a timely manner, the ability to successfully develop our product candidate and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements as discussed in “Risk Factors” and elsewhere in Lumos Pharma’s Annual Report on Form 10-K for the year ended December 31, 2020 and other reports filed with the SEC. The forward-looking statements in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause their views to change. However, while it may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this press release.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
[email protected]



electroCore to Present at the Canaccord Genuity Growth Conference

ROCKAWAY, NJ, Aug. 02, 2021 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will give a corporate presentation and be available for virtual one-on-one meetings at the Canaccord Genuity Growth Conference. The conference is taking place virtually from August 10 – 12, 2021. Details for the presentation are as follows:

Canaccord Genuity Growth Conference:

Date: Thursday, August 12, 2021
Time: 8:30 am EDT
Investors can register for the conference HERE.

Following the conference a webcast replay of the presentation will be available on the Investor section of the company’s website, www.electrocore.com.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine and the acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.



Investors:
Rich Cockrell
CG Capital
404-736-3838
[email protected]

or

Media Contact:
Jackie Dorsky
electroCore
908-313-6331
[email protected]

Resources Global Professionals Announces Quarterly Dividend and Dividend Payment Date

Resources Global Professionals Announces Quarterly Dividend and Dividend Payment Date

IRVINE, Calif.–(BUSINESS WIRE)–Resources Global Professionals (“RGP”), the operating subsidiary of Resources Connection, Inc. (Nasdaq: RGP), announced today that the Board of Directors of its parent company has approved a cash dividend of $0.14 per share, payable on September 23, 2021 to all shareholders of record on August 26, 2021.

ABOUT RGP

RGP is a global consulting firm that enables rapid business outcomes by bringing together the right people to create transformative change. As a human capital partner to our global client base, we support our clients’ needs through both professional staffing and project execution in the areas of transactions, regulations, and transformations. Our pioneering approach to workforce strategy and our agile human capital model quickly align the right resources for the work at hand with speed and efficiency. Our engagements are designed to leverage human connection and collaboration to deliver practical solutions and more impactful results that power our clients’, consultants’ and partners’ success. Our mission as an employer is to connect our team members to meaningful opportunities that further their career ambitions within the context of a supportive talent community of dedicated professionals. With approximately 5,000 professionals, we annually engage with over 2,100 clients around the world from over 40 physical practice offices and multiple virtual offices. We are their partner in delivering on the future of work. Headquartered in Irvine, California, RGP is proud to have served over 85% of the Fortune 100.

The Company is listed on the Nasdaq Global Select Market, the exchange’s highest tier by listing standards. To learn more about RGP, visit: http://www.rgp.com. (RGP-F)

Media Contact:

Michael Sitrick

(US+) 1-310-788-2850

[email protected]

Investor Contact:

Jenn Ryu, Chief Financial Officer

(US+) 1-714-430-6500

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Consulting Other Professional Services Professional Services Human Resources

MEDIA:

Logo
Logo

ON Semiconductor Reports Record Revenue and Non-GAAP Earnings per Share for Second Quarter 2021

ON Semiconductor Reports Record Revenue and Non-GAAP Earnings per Share for Second Quarter 2021

PHOENIX–(BUSINESS WIRE)–
ON Semiconductor Corporation (Nasdaq: ON) today announced results for the second quarter of 2021 with the following highlights:

  • Record revenue of $1,669.9 million, an increase of 38 percent year-over-year
  • GAAP diluted earnings per share of $0.42 as compared to $0.00 in the quarter a year ago
  • Record non-GAAP diluted earnings per share of $0.63 as compared to $0.12 in the quarter a year ago
  • GAAP gross margin of 38.3 percent increased 310 basis points quarter-over-quarter and 750 basis points year-over-year
  • Non-GAAP gross margin of 38.4 percent increased 320 basis points quarter-over-quarter and 760 basis points year-over-year
  • Record free cash flow of $383.2 million or 22.9% of revenue

“Our strong second quarter results were driven by solid execution and ongoing structural changes, in addition to a strong demand environment. We posted yet another quarter of non-GAAP gross margin expansion with margins increasing by 320 basis points quarter-over-quarter. We expect that the ongoing structural changes in the business should enable us to report strong results on a sustainable basis. While we are encouraged by our recent results, we will continue to transform the business to realize its full potential,” said Hassane El-Khoury, president and CEO of ON Semiconductor.

“We continue to see accelerating demand for our products in our strategic automotive and industrial end-markets. As we continue to drive operational efficiencies in our manufacturing sites, we expect to see incremental supply and revenue growth in the second half of 2021.”

Selected financial results for the quarter are shown below with comparable periods:

 

 

GAAP

 

Non-GAAP

(in millions, except per share data)

 

Q2 2021

 

Q1 2021

 

Q2 2020

 

Q2 2021

 

Q1 2021

 

Q2 2020

Revenue

 

$1,669.9

 

$1,481.7

 

$1,213.5

 

$1,669.9

 

$1,481.7

 

$1,213.5

Gross Margin

 

38.3%

 

35.2%

 

30.8%

 

38.4%

 

35.2%

 

30.8%

Operating Margin

 

16.9%

 

8.5%

 

3.6%

 

19.6%

 

13.3%

 

7.4%

Net Income (Loss) Attributable to ON Semiconductor Corporation

 

$184.1

 

$89.9

 

($1.4)

 

$275.8

 

$151.3

 

$50.2

Diluted Earnings (Loss) Per Share

 

$0.42

 

$0.20

 

$0.00

 

$0.63

 

$0.35

 

$0.12

 

Revenue Summary

($ in millions)

(Unaudited)

 

 

Three Months Ended

 

 

 

 

Business Segment

 

Q2 2021

 

Q1 2021

 

Q2 2020

 

Sequential

Change

 

Year over Year

Change

PSG

 

$

846.6

 

 

$

747.0

 

 

$

618.4

 

 

13

%

 

37

%

ASG

 

607.6

 

 

531.5

 

 

426.7

 

 

14

%

 

42

%

ISG

 

215.7

 

 

203.2

 

 

168.4

 

 

6

%

 

28

%

Total

 

$

1,669.9

 

 

$

1,481.7

 

 

$

1,213.5

 

 

13

%

 

38

%

THIRD QUARTER 2021 OUTLOOK

The following table outlines ON Semiconductor’s projected third quarter of 2021 GAAP and non-GAAP outlook.

 

 

Total ON Semiconductor

GAAP

 

Special

Items ***

 

Total ON Semiconductor

Non-GAAP****

Revenue

 

$1,660 to $1,760 million

 

 

 

$1,660 to $1,760 million

Gross Margin

 

38.8% to 40.9%

 

0.1% to 0.2%

 

39.0% to 41.0%

Operating Expenses

 

$331 to $346 million

 

$26 million

 

$305 to $320 million

Other Income and Expense (including interest expense), net

 

$33 to $36 million

 

$7 million*

 

$26 to $29 million

Diluted Earnings Per Share

 

$0.53 to $ 0.63

 

$0.15 to $ 0.17

 

$0.68 to $0.80

Diluted Shares Outstanding **

 

440 million

 

4 million

 

436 million

*

 

Convertible Notes, Non-cash interest expense is calculated pursuant to FASB’s Accounting Standards Codification Topic 470: Debt.

 

**

 

Diluted shares outstanding can vary as a result of, among other things, the actual exercise of options or vesting of restricted stock units, the incremental dilutive shares from the Company’s convertible senior subordinated notes, and the repurchase or the issuance of stock or convertible notes or the sale of treasury shares. In periods when the quarterly average stock price per share exceeds $20.72 for the 1.625% Notes and $52.97 for the 0% Notes, the non-GAAP diluted share count and non-GAAP net income per share include the anti-dilutive impact of the Company’s hedge transactions issued concurrently with the 1.625% Notes and the 0% Notes, respectively. At an average stock price per share between $20.72 and $30.70 for the 1.625% Notes and $52.97 and $74.34 for the 0% Notes, the hedging activity offsets the potentially dilutive effect of the 1.625% Notes and 0% Notes, respectively. In periods when the quarterly average stock price exceeds $30.70 for the 1.625% Notes, and $74.34 for the 0% Notes, the dilutive impact of the warrants issued concurrently with such notes are included in the diluted shares outstanding. Both GAAP and non-GAAP diluted share counts are based on the Company’s stock price as of July 2, 2021.

 

***

 

Special items may include: amortization of acquisition-related intangibles; expensing of appraised inventory fair market value step-up; non-recurring facility costs, purchased in-process research and development expenses; restructuring, asset impairments and other, net; goodwill impairment charges; gains and losses on debt prepayment; non-cash interest expense; actuarial (gains) losses on pension plans and other pension benefits; and certain other special items, as necessary. These special items are out of our control and could change significantly from period to period. As a result, we are not able to reasonably estimate and separately present the individual impact or probable significance of these special items, and we are similarly unable to provide a reconciliation of the non-GAAP measures. The reconciliation that is unavailable would include a forward-looking income statement, balance sheet and statement of cash flows in accordance with GAAP. For this reason, we use a projected range of the aggregate amount of special items in order to calculate our projected non-GAAP operating expense outlook.

 

****

 

We believe these non-GAAP measures provide important supplemental information to investors. We use these measures, together with GAAP measures, for internal managerial purposes and as a means to evaluate period-to-period comparisons. However, we do not, and you should not, rely on non-GAAP financial measures alone as measures of our performance. We believe that non-GAAP financial measures reflect an additional way of viewing aspects of our operations that, when taken together with GAAP results and the reconciliations to corresponding GAAP financial measures that we also provide in our releases, provide a more complete understanding of factors and trends affecting our business. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies’ non-GAAP financial measures, even if they have similar names.

TELECONFERENCE

ON Semiconductor will host a conference call for the financial community at 9 a.m. Eastern Daylight Time (EDT) on August 2, 2021 to discuss this announcement and ON Semiconductor’s 2021 second quarter results. The Company will also provide a real-time audio webcast of the teleconference on the Investor Relations page of its website at http://www.onsemi.com. The webcast replay will be available at this site approximately one hour following the live broadcast and will continue to be available for approximately 30 days following the conference call. Investors and interested parties can also access the conference call via telephone by dialing (833) 303-2043 (U.S./Canada) or: (236) 714-3942 (International). In order to join this conference call, you will be required to provide the Conference ID Number – which is 7573025.

About ON Semiconductor

ON Semiconductor (Nasdaq: ON) is driving energy efficient electronics innovations that help make the world greener, safer, inclusive and connected. The company has transformed into our customers’ supplier of choice for power, analog, sensor and connectivity solutions. The company’s superior products help engineers solve their most unique design challenges in automotive, industrial, cloud power, and Internet of Things (IoT) applications. For more information, visit http://www.onsemi.com.

ON Semiconductor and the ON Semiconductor logo are registered trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders. Although the Company references its website in this news release, information on the website is not to be incorporated herein.

This document includes “forward-looking statements,” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated in this document could be deemed forward-looking statements, particularly statements about the future financial performance of ON Semiconductor, including financial guidance for the year ending December 31, 2021. Forward-looking statements are often characterized by the use of words such as “believes,” “estimates,” “expects,” “projects,” “may,” “will,” “intends,” “plans” or “anticipates” or by discussions of strategy, plans or intentions. All forward-looking statements in this document are made based on our current expectations, forecasts, estimates and assumptions and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. Certain factors that could affect our future results or events are described under Part I, Item 1A “Risk Factors” in our 2020 Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 16, 2021 (our “2020 Form 10-K”) and from time to time in our other SEC reports. Readers are cautioned not to place undue reliance on forward-looking statements. We assume no obligation to update such information, except as may be required by law. You should carefully consider the trends, risks and uncertainties described in this document, our 2020 Form 10-K and subsequent reports filed with or furnished to the SEC before making any investment decision with respect to our securities. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, and you could lose all or part of your investment. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

ON SEMICONDUCTOR CORPORATION

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data)

 

 

Quarters Ended

 

Six Months Ended

 

 

July 2, 2021

 

April 2, 2021

 

July 3, 2020

 

July 2, 2021

 

July 3, 2020

Revenue

 

$

1,669.9

 

 

$

1,481.7

 

 

$

1,213.5

 

 

$

3,151.6

 

 

$

2,491.4

 

Cost of revenue (exclusive of amortization shown below)

 

1,029.8

 

 

960.5

 

 

839.2

 

 

1,990.3

 

 

1,714.4

 

Gross profit

 

640.1

 

 

521.2

 

 

374.3

 

 

1,161.3

 

 

777.0

 

Gross margin

 

38.3

%

 

35.2

%

 

30.8

%

 

36.8

%

 

31.2

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

Research and development

 

166.3

 

 

173.6

 

 

156.1

 

 

339.9

 

 

327.1

 

Selling and marketing

 

76.1

 

 

78.9

 

 

65.6

 

 

155.0

 

 

142.4

 

General and administrative

 

73.2

 

 

72.4

 

 

62.9

 

 

145.6

 

 

134.1

 

Amortization of acquisition-related intangible assets

 

24.8

 

 

25.0

 

 

29.1

 

 

49.8

 

 

61.4

 

Restructuring, asset impairments and other charges, net

 

17.5

 

 

42.5

 

 

16.2

 

 

60.0

 

 

49.0

 

Intangible asset impairment

 

 

 

2.9

 

 

1.3

 

 

2.9

 

 

1.3

 

Total operating expenses

 

357.9

 

 

395.3

 

 

331.2

 

 

753.2

 

 

715.3

 

Operating income

 

282.2

 

 

125.9

 

 

43.1

 

 

408.1

 

 

61.7

 

Other income (expense), net:

 

 

 

 

 

 

 

 

 

 

Interest expense

 

(33.1)

 

 

(33.4)

 

 

(41.9)

 

 

(66.5)

 

 

(84.4)

 

Interest income

 

0.2

 

 

0.4

 

 

1.5

 

 

0.6

 

 

3.4

 

Loss on debt refinancing and prepayment

 

(26.2)

 

 

 

 

 

 

(26.2)

 

 

 

Other income (expense)

 

(1.1)

 

 

4.5

 

 

(2.8)

 

 

3.4

 

 

(2.7)

 

Other income (expense), net

 

(60.2)

 

 

(28.5)

 

 

(43.2)

 

 

(88.7)

 

 

(83.7)

 

Income (loss) before income taxes

 

222.0

 

 

97.4

 

 

(0.1)

 

 

319.4

 

 

(22.0)

 

Income tax (provision) benefit

 

(37.9)

 

 

(7.1)

 

 

(0.8)

 

 

(45.0)

 

 

7.4

 

Net income (loss)

 

184.1

 

 

90.3

 

 

(0.9)

 

 

274.4

 

 

(14.6)

 

Less: Net income attributable to non-controlling interest

 

 

 

(0.4)

 

 

(0.5)

 

 

(0.4)

 

 

(0.8)

 

Net income (loss) attributable to ON Semiconductor Corporation

 

$

184.1

 

 

$

89.9

 

 

$

(1.4)

 

 

$

274.0

 

 

$

(15.4)

 

Net income (loss) per common share attributable to ON Semiconductor Corporation:

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0.43

 

 

$

0.22

 

 

$

 

 

$

0.65

 

 

$

(0.04)

 

Diluted

 

$

0.42

 

 

$

0.20

 

 

$

 

 

$

0.62

 

 

$

(0.04)

 

Weighted average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

Basic

 

427.7

 

 

413.4

 

 

410.1

 

 

420.5

 

 

410.3

 

Diluted

 

443.6

 

 

445.4

 

 

410.1

 

 

444.5

 

 

410.3

 

ON SEMICONDUCTOR CORPORATION

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in millions)

 

July 2, 2021

 

April 2, 2021

 

December 31, 2020

Assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

1,091.1

 

 

$

1,042.5

 

 

$

1,080.7

 

Receivables, net

 

669.1

 

 

683.6

 

 

676.0

 

Inventories

 

1,309.3

 

 

1,295.5

 

 

1,251.4

 

Other current assets

 

160.4

 

 

166.0

 

 

176.0

 

Total current assets

 

3,229.9

 

 

3,187.6

 

 

3,184.1

 

Property, plant and equipment, net

 

2,457.8

 

 

2,489.4

 

 

2,512.3

 

Goodwill

 

1,663.4

 

 

1,663.4

 

 

1,663.4

 

Intangible assets, net

 

416.3

 

 

441.1

 

 

469.0

 

Deferred tax assets

 

429.9

 

 

447.2

 

 

429.0

 

Other assets

 

397.1

 

 

401.7

 

 

410.2

 

Total assets

 

$

8,594.4

 

 

$

8,630.4

 

 

$

8,668.0

 

Liabilities, Non-Controlling Interest and Stockholders’ Equity

 

 

 

 

 

 

Accounts payable

 

$

610.2

 

 

$

605.0

 

 

$

572.9

 

Accrued expenses and other current liabilities

 

643.6

 

 

588.3

 

 

570.0

 

Current portion of long-term debt

 

201.3

 

 

536.7

 

 

531.6

 

Total current liabilities

 

1,455.1

 

 

1,730.0

 

 

1,674.5

 

Long-term debt

 

2,907.1

 

 

2,806.9

 

 

2,959.7

 

Deferred tax liabilities

 

49.8

 

 

53.9

 

 

57.3

 

Other long-term liabilities

 

378.0

 

 

390.0

 

 

418.4

 

Total liabilities

 

4,790.0

 

 

4,980.8

 

 

5,109.9

 

ON Semiconductor Corporation stockholders’ equity:

 

 

 

 

 

 

Common stock

 

6.0

 

 

5.8

 

 

5.7

 

Additional paid-in capital

 

4,470.3

 

 

4,161.0

 

 

4,133.1

 

Accumulated other comprehensive loss

 

(52.2)

 

 

(55.9)

 

 

(57.6)

 

Accumulated earnings

 

1,699.5

 

 

1,515.4

 

 

1,425.5

 

Less: Treasury stock, at cost

 

(2,339.2)

 

 

(1,996.7)

 

 

(1,968.2)

 

Total ON Semiconductor Corporation stockholders’ equity

 

3,784.4

 

 

3,629.6

 

 

3,538.5

 

Non-controlling interest

 

20.0

 

 

$

20.0

 

 

19.6

 

Total stockholders’ equity

 

3,804.4

 

 

3,649.6

 

 

3,558.1

 

Total liabilities and stockholders’ equity

 

$

8,594.4

 

 

$

8,630.4

 

 

$

8,668.0

 

ON SEMICONDUCTOR CORPORATION

UNAUDITED RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA AND

NET CASH PROVIDED BY OPERATING ACTIVITIES

(in millions) 

 

 

Quarters Ended

 

Six Months Ended

 

 

July 2, 2021

 

April 2, 2021

 

July 3, 2020

 

July 2, 2021

 

July 3, 2020

Net income (loss)

 

$

184.1

 

 

$

90.3

 

 

$

(0.9)

 

 

$

274.4

 

 

$

(14.6)

 

Adjusted for:

 

 

 

 

 

 

 

 

 

 

Restructuring, asset impairments and other charges, net

 

17.5

 

 

42.5

 

 

16.2

 

 

60.0

 

 

49.0

 

Intangible asset impairment

 

 

 

2.9

 

 

1.3

 

 

2.9

 

 

1.3

 

Interest expense

 

33.1

 

 

33.4

 

 

41.9

 

 

66.5

 

 

84.4

 

Interest income

 

(0.2)

 

 

(0.4)

 

 

(1.5)

 

 

(0.6)

 

 

(3.4)

 

Loss on debt refinancing and prepayment

 

26.2

 

 

 

 

 

 

26.2

 

 

 

Income tax provision (benefit)

 

37.9

 

 

7.1

 

 

0.8

 

 

45.0

 

 

(7.4)

 

Net income attributable to non-controlling interest

 

 

 

(0.4)

 

 

(0.5)

 

 

(0.4)

 

 

(0.8)

 

Depreciation and amortization

 

153.1

 

 

153.4

 

 

153.9

 

 

306.5

 

 

315.1

 

Third party acquisition and divestiture related costs

 

1.4

 

 

0.2

 

 

 

 

1.6

 

 

0.3

 

Adjusted EBITDA

 

453.1

 

 

329.0

 

 

211.2

 

 

782.1

 

 

423.9

 

Increase (decrease):

 

 

 

 

 

 

 

 

 

 

Restructuring, asset impairments and other, net

 

(17.5)

 

 

(42.5)

 

 

(16.2)

 

 

(60.0)

 

 

(49.0)

 

Interest expense

 

(33.1)

 

 

(33.4)

 

 

(41.9)

 

 

(66.5)

 

 

(84.4)

 

Interest income

 

0.2

 

 

0.4

 

 

1.5

 

 

0.6

 

 

3.4

 

Income tax (provision) benefit

 

(37.9)

 

 

(7.1)

 

 

(0.8)

 

 

(45.0)

 

 

7.4

 

Net income attributable to non-controlling interest

 

 

 

0.4

 

 

0.5

 

 

0.4

 

 

0.8

 

Third party acquisition and divestiture related costs

 

(1.4)

 

 

(0.2)

 

 

 

 

(1.6)

 

 

(0.3)

 

Loss (gain) on sale or disposal of fixed assets

 

 

 

0.3

 

 

(3.1)

 

 

0.3

 

 

(2.9)

 

Amortization of debt discount and issuance costs

 

2.7

 

 

2.4

 

 

3.0

 

 

5.1

 

 

6.0

 

Share-based compensation

 

29.1

 

 

22.3

 

 

18.0

 

 

51.4

 

 

33.7

 

Non-cash interest on convertible notes

 

6.0

 

 

4.6

 

 

9.8

 

 

10.6

 

 

19.3

 

Non-cash asset impairment charges

 

1.4

 

 

3.2

 

 

5.8

 

 

4.6

 

 

7.2

 

Change in deferred tax balances

 

18.5

 

 

(23.2)

 

 

6.7

 

 

(4.7)

 

 

(12.3)

 

Other

 

2.0

 

 

(2.0)

 

 

1.8

 

 

 

 

1.8

 

Changes in assets and liabilities

 

64.9

 

 

(35.7)

 

 

(41.8)

 

 

29.2

 

 

(34.1)

 

Net cash provided by operating activities

 

$

488.0

 

 

$

218.5

 

 

$

154.5

 

 

$

706.5

 

 

$

320.5

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

$

(104.8)

 

 

$

(77.0)

 

 

$

(73.3)

 

 

$

(181.8)

 

 

$

(205.6)

 

Deposits and proceeds from sale of property, plant and equipment

 

6.4

 

 

0.2

 

 

0.9

 

 

6.6

 

 

0.9

 

Deposits utilized (made) for purchase of property, plant and equipment

 

(2.4)

 

 

(0.4)

 

 

(1.7)

 

 

(2.8)

 

 

0.5

 

Purchase of business, net of cash acquired

 

 

 

 

 

 

 

 

 

(4.5)

 

Settlement of purchase price from previous acquisition

 

 

 

 

 

 

 

 

 

26.0

 

Net cash used in investing activities

 

$

(100.8)

 

 

$

(77.2)

 

 

$

(74.1)

 

 

$

(178.0)

 

 

$

(182.7)

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

Proceeds for the issuance of common stock under the ESPP

 

$

5.7

 

 

$

6.6

 

 

$

3.9

 

 

$

12.3

 

 

$

11.4

 

Payment of tax withholding for restricted stock units

 

(3.5)

 

 

(28.5)

 

 

(0.6)

 

 

(32.0)

 

 

(16.6)

 

Repurchase of common stock

 

 

 

 

 

 

 

 

 

(65.4)

 

Issuance and borrowings under debt agreements

 

787.3

 

 

 

 

 

 

787.3

 

 

1,165.0

 

Reimbursement of debt issuance costs

 

2.7

 

 

 

 

 

 

2.7

 

 

 

Payment of debt issuance costs

 

(3.5)

 

 

 

 

 

 

(3.5)

 

 

 

Repayment of borrowings under debt agreements

 

(1,060.6)

 

 

(154.1)

 

 

(4.3)

 

 

(1,214.7)

 

 

(60.3)

 

Payments related to prior acquisition

 

(0.2)

 

 

(2.1)

 

 

(0.6)

 

 

(2.3)

 

 

(5.5)

 

Payment for purchase of bond hedges

 

(160.3)

 

 

 

 

 

 

(160.3)

 

 

 

Proceeds from issuance of warrants

 

93.8

 

 

 

 

 

 

93.8

 

 

 

Net cash provided by (used in) financing activities

 

$

(338.6)

 

 

$

(178.1)

 

 

$

(1.6)

 

 

$

(516.7)

 

 

$

1,028.6

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

 

(0.8)

 

 

(0.1)

 

 

(0.8)

 

 

0.1

 

Net increase (decrease) in cash, cash equivalents and restricted cash

 

$

48.6

 

 

$

(37.6)

 

 

$

78.7

 

 

$

11.0

 

 

$

1,166.5

 

Beginning cash, cash equivalents and restricted cash

 

1,043.9

 

 

1,081.5

 

 

1,982.0

 

 

1,081.5

 

 

894.2

 

Ending cash, cash equivalents and restricted cash

 

$

1,092.5

 

 

$

1,043.9

 

 

$

2,060.7

 

 

$

1,092.5

 

 

$

2,060.7

 

ON SEMICONDUCTOR CORPORATION

RECONCILIATION OF GAAP VERSUS NON-GAAP DISCLOSURES

(in millions, except per share and percentage data)

 

 

 

 

Quarters Ended

 

Six Months Ended

 

 

 

 

July 2, 2021

 

April 2, 2021

 

July 3, 2020

 

July 2, 2021

 

July 3, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of GAAP to non-GAAP gross profit:

 

 

 

 

 

 

 

 

 

 

GAAP gross profit

 

$

640.1

 

 

$

521.2

 

 

$

374.3

 

 

$

1,161.3

 

 

$

777.0

 

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Non-recurring facility costs

 

0.7

 

 

 

 

 

 

0.7

 

 

 

 

 

Total special items

 

0.7

 

 

 

 

 

 

0.7

 

 

 

Non-GAAP gross profit

 

$

640.8

 

 

$

521.2

 

 

$

374.3

 

 

$

1,162.0

 

 

$

777.0

 

Reconciliation of GAAP to non-GAAP gross margin:

 

 

 

 

 

 

 

 

 

 

GAAP gross margin

 

38.3

%

 

35.2

%

 

30.8

%

 

36.8

%

 

31.2

%

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Non-recurring facility costs

 

%

 

%

 

%

 

%

 

%

 

 

Total special items

 

0.1

%

 

%

 

%

 

0.1

%

 

%

Non-GAAP gross margin

 

38.4

%

 

35.2

%

 

30.8

%

 

36.9

%

 

31.2

%

Reconciliation of GAAP to non-GAAP operating expenses:

 

 

 

 

 

 

 

 

 

 

GAAP operating expenses

 

$

357.9

 

 

$

395.3

 

 

$

331.2

 

 

$

753.2

 

 

$

715.3

 

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Amortization of acquisition-related intangible assets

 

(24.8)

 

 

(25.0)

 

 

(29.1)

 

 

(49.8)

 

 

(61.4)

 

 

b)

Restructuring, asset impairments and other, net

 

(17.5)

 

 

(42.5)

 

 

(16.2)

 

 

(60.0)

 

 

(49.0)

 

 

c)

Intangible asset impairment

 

 

 

(2.9)

 

 

(1.3)

 

 

(2.9)

 

 

(1.3)

 

 

d)

Third party acquisition and divestiture related costs

 

(1.4)

 

 

(0.2)

 

 

 

 

(1.6)

 

 

(0.3)

 

 

 

Total special items

 

(43.7)

 

 

(70.6)

 

 

(46.6)

 

 

(114.3)

 

 

(112.0)

 

Non-GAAP operating expenses

 

$

314.2

 

 

$

324.7

 

 

$

284.6

 

 

$

638.9

 

 

$

603.3

 

Reconciliation of GAAP to non-GAAP operating income:

 

 

 

 

 

 

 

 

 

 

GAAP operating income

 

$

282.2

 

 

$

125.9

 

 

$

43.1

 

 

$

408.1

 

 

$

61.7

 

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Non-recurring facility costs

 

0.7

 

 

 

 

 

 

0.7

 

 

 

 

b)

Amortization of acquisition-related intangible assets

 

24.8

 

 

25.0

 

 

29.1

 

 

49.8

 

 

61.4

 

 

c)

Restructuring, asset impairments and other, net

 

17.5

 

 

42.5

 

 

16.2

 

 

60.0

 

 

49.0

 

 

d)

Intangible asset impairment

 

 

 

2.9

 

 

1.3

 

 

2.9

 

 

1.3

 

 

e)

Third party acquisition and divestiture related costs

 

1.4

 

 

0.2

 

 

 

 

1.6

 

 

0.3

 

 

 

Total special items

 

44.4

 

 

70.6

 

 

46.6

 

 

115.0

 

 

112.0

 

Non-GAAP operating income

 

$

326.6

 

 

$

196.5

 

 

$

89.7

 

 

$

523.1

 

 

$

173.7

 

Reconciliation of GAAP to non-GAAP operating margin (operating income / revenue):

 

 

 

 

 

 

 

 

 

 

GAAP operating margin

 

16.9

%

 

8.5

%

 

3.6

%

 

12.9

%

 

2.5

%

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Non-recurring facility costs

 

%

 

%

 

%

 

%

 

%

 

b)

Amortization of acquisition-related intangible assets

 

1.5

%

 

1.7

%

 

2.4

%

 

1.6

%

 

2.5

%

 

c)

Restructuring, asset impairments and other, net

 

1.0

%

 

2.9

%

 

1.3

%

 

1.9

%

 

2.0

%

 

d)

Intangible asset impairment

 

%

 

0.2

%

 

0.1

%

 

0.1

%

 

0.1

%

 

e)

Third party acquisition and divestiture related costs

 

0.1

%

 

%

 

%

 

0.1

%

 

%

 

 

Total special items

 

2.7

%

 

4.8

%

 

3.8

%

 

3.7

%

 

4.5

%

Non-GAAP operating margin

 

19.6

%

 

13.3

%

 

7.4

%

 

16.6

%

 

7.0

%

Reconciliation of GAAP to non-GAAP income before income taxes:

 

 

 

 

 

 

 

 

 

 

GAAP income (loss) before income taxes

 

$

222.0

 

 

$

97.4

 

 

$

(0.1)

 

 

$

319.4

 

 

$

(22.0)

 

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Non-recurring facility costs

 

0.7

 

 

 

 

 

 

0.7

 

 

 

 

b)

Amortization of acquisition-related intangible assets

 

24.8

 

 

25.0

 

 

29.1

 

 

49.8

 

 

61.4

 

 

c)

Restructuring, asset impairments and other, net

 

17.5

 

 

42.5

 

 

16.2

 

 

60.0

 

 

49.0

 

 

d)

Intangible asset impairment

 

 

 

2.9

 

 

1.3

 

 

2.9

 

 

1.3

 

 

e)

Third party acquisition and divestiture related costs

 

1.4

 

 

0.2

 

 

 

 

1.6

 

 

0.3

 

 

f)

Loss on debt refinancing and repayment

 

26.2

 

 

 

 

 

 

26.2

 

 

 

 

g)

Non-cash interest on convertible notes

 

6.0

 

 

4.6

 

 

9.8

 

 

10.6

 

 

19.3

 

 

 

Total special items

 

76.6

 

 

75.2

 

 

56.4

 

 

151.8

 

 

131.3

 

Non-GAAP income before income taxes

 

$

298.6

 

 

$

172.6

 

 

$

56.3

 

 

$

471.2

 

 

$

109.3

 

Reconciliation of GAAP to non-GAAP net income attributable to ON Semiconductor Corporation:

 

 

 

 

 

 

 

 

 

 

GAAP net income (loss) attributable to ON Semiconductor Corporation

 

$

184.1

 

 

$

89.9

 

 

$

(1.4)

 

 

$

274.0

 

 

$

(15.4)

 

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Non-recurring facility costs

 

0.7

 

 

 

 

 

 

0.7

 

 

 

 

b)

Amortization of acquisition-related intangible assets

 

24.8

 

 

25.0

 

 

29.1

 

 

49.8

 

 

61.4

 

 

c)

Restructuring, asset impairments and other, net

 

17.5

 

 

42.5

 

 

16.2

 

 

60.0

 

 

49.0

 

 

d)

Intangible asset impairment

 

 

 

2.9

 

 

1.3

 

 

2.9

 

 

1.3

 

 

e)

Third party acquisition and divestiture related costs

 

1.4

 

 

0.2

 

 

 

 

1.6

 

 

0.3

 

 

f)

Loss on debt refinancing and prepayment

 

26.2

 

 

 

 

 

 

26.2

 

 

 

 

g)

Non-cash interest on convertible notes

 

6.0

 

 

4.6

 

 

9.8

 

 

10.6

 

 

19.3

 

 

h)

Adjustment of income taxes

 

15.1

 

 

(13.8)

 

 

(4.8)

 

 

1.3

 

 

(22.9)

 

 

 

Total special items

 

91.7

 

 

61.4

 

 

51.6

 

 

153.1

 

 

108.4

 

Non-GAAP net income attributable to ON Semiconductor Corporation

 

$

275.8

 

 

$

151.3

 

 

$

50.2

 

 

$

427.1

 

 

$

93.0

 

Adjustment of income taxes:

 

 

 

 

 

 

 

 

 

 

Tax adjustment for special items (1)

 

$

(16.1)

 

 

$

(15.8)

 

 

$

(11.8)

 

 

$

(31.9)

 

 

$

(27.6)

 

Other non-GAAP tax adjustment (2)

 

31.2

 

 

2.0

 

 

7.0

 

 

33.2

 

 

4.7

 

 

 

Total adjustment of income taxes

 

$

15.1

 

 

$

(13.8)

 

 

$

(4.8)

 

 

$

1.3

 

 

$

(22.9)

 

Reconciliation of GAAP to non-GAAP diluted shares outstanding:

 

 

 

 

 

 

 

 

 

 

GAAP diluted shares outstanding

 

443.6

 

 

445.4

 

 

410.1

 

 

444.5

 

 

410.3

 

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Less: dilutive shares attributable to convertible notes

 

(8.6)

 

 

(12.8)

 

 

 

 

(10.7)

 

 

 

 

b)

Add: dilutive shares attributable to share-based awards

 

 

 

 

 

0.9

 

 

 

 

1.6

 

 

 

Total special items

 

(8.6)

 

 

(12.8)

 

 

0.9

 

 

(10.7)

 

 

1.6

 

Non-GAAP diluted shares outstanding

 

435.0

 

 

432.6

 

 

411.0

 

 

433.8

 

 

411.9

 

Non-GAAP diluted earnings per share:

 

 

 

 

 

 

 

 

 

 

Non-GAAP net income attributable to ON Semiconductor Corporation

 

$

275.8

 

 

$

151.3

 

 

$

50.2

 

 

$

427.1

 

 

$

93.0

 

Non-GAAP diluted shares outstanding

 

435.0

 

 

432.6

 

 

411.0

 

 

433.8

 

 

411.9

 

Non-GAAP diluted earnings per share

 

$

0.63

 

 

$

0.35

 

 

$

0.12

 

 

$

0.98

 

 

$

0.23

 

Reconciliation of net cash provided by operating activities to free cash flow:

 

 

 

 

 

 

 

 

 

 

Net cash provided by operating activities

 

$

488.0

 

 

$

218.5

 

 

$

154.5

 

 

$

706.5

 

 

$

320.5

 

 

Special items:

 

 

 

 

 

 

 

 

 

 

 

a)

Purchase of property, plant and equipment

 

(104.8)

 

 

(77.0)

 

 

(73.3)

 

 

(181.8)

 

 

(205.6)

 

 

 

Total special items

 

(104.8)

 

 

(77.0)

 

 

(73.3)

 

 

(181.8)

 

 

(205.6)

 

Free cash flow

 

$

383.2

 

 

$

141.5

 

 

$

81.2

 

 

$

524.7

 

 

$

114.9

 

(1)

 

Tax impact of non-GAAP special items (a-g) is calculated using the federal statutory rate of 21% for all periods presented.

(2)

 

The income tax adjustment primarily represents the use of the net operating loss, non-cash impact of not asserting indefinite reinvestment on earnings of our foreign subsidiaries, deferred tax expense not affecting taxes payable, and non-cash expense (benefit) related to uncertain tax positions.

Certain of the amounts in the above tables may not total due to rounding of individual amounts.

Total share-based compensation related to the Company’s restricted stock units, stock grant awards and employee stock purchase plan is included below:

 

 

Quarters Ended

 

Six Months Ended

 

 

July 2, 2021

 

April 2, 2021

 

July 3, 2020

 

July 2, 2021

 

July 3, 2020

Cost of revenue

 

$

4.9

 

 

$

3.3

 

 

$

2.8

 

 

$

8.2

 

 

$

5.3

 

Research and development

 

7.3

 

 

5.7

 

 

4.4

 

 

13.0

 

 

8.5

 

Selling and marketing

 

4.5

 

 

4.3

 

 

3.1

 

 

8.8

 

 

6.1

 

General and administrative

 

12.4

 

 

9.0

 

 

7.7

 

 

21.4

 

 

13.8

 

Total share-based compensation

 

$

29.1

 

 

$

22.3

 

 

$

18.0

 

 

$

51.4

 

 

$

33.7

 

SUPPLEMENTAL FINANCIAL DATA

 

 

Quarters Ended

 

Six Months Ended

 

 

July 2, 2021

 

April 2, 2021

 

July 3, 2020

 

July 2, 2021

 

July 3, 2020

Net cash provided by operating activities

 

$

488.0

 

 

$

218.5

 

 

$

154.5

 

 

$

706.5

 

 

$

320.5

 

Free cash flow

 

383.2

 

 

141.5

 

 

81.2

 

 

524.7

 

 

114.9

 

Cash paid for income taxes

 

22.8

 

 

20.9

 

 

5.6

 

 

43.7

 

 

15.5

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

$

153.1

 

 

$

153.4

 

 

$

153.9

 

 

$

306.5

 

 

$

315.1

 

Less: Amortization of acquisition-related intangible assets

 

24.8

 

 

25.0

 

 

29.1

 

 

49.8

 

 

61.4

 

Depreciation and amortization (excl. amortization of acquisition-related intangible assets)

 

$

128.3

 

 

$

128.4

 

 

$

124.8

 

 

$

256.7

 

 

$

253.7

 

To supplement the consolidated financial results prepared in accordance with GAAP, ON Semiconductor uses certain non-GAAP measures, which are adjusted from the most directly comparable GAAP measures to exclude items related to the amortization of intangible assets, amortization of acquisition-related intangibles, expensing of appraised inventory fair market value step-up, inventory valuation adjustments, purchased in-process research and development expenses, restructuring, asset impairments and other, net, goodwill impairment charges, gains and losses on debt prepayment, non-cash interest expense, actuarial (gains) losses on pension plans and other pension benefits, third party acquisition and divestiture related costs, tax impact of these items and certain other non-recurring items, as necessary. Management does not consider the effects of these items in evaluating the core operational activities of ON Semiconductor. Management uses these non-GAAP measures internally to make strategic decisions, forecast future results and evaluate ON Semiconductor’s current performance. In addition, the Company believes that most analysts covering ON Semiconductor use the non-GAAP measures to evaluate ON Semiconductor’s performance. Given management’s and other relevant use of these non-GAAP measures, ON Semiconductor believes these measures are important to investors in understanding ON Semiconductor’s current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in ON Semiconductor’s core business across different time periods. These non-GAAP measures are not prepared in accordance with, and should not be considered alternatives or necessarily superior to, GAAP financial data and may be different from non-GAAP measures used by other companies. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies’ non-GAAP financial measures, even if they have similar names.

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that represents net income before interest expense, interest income, provision for income taxes, depreciation and amortization expense and special items. We use the adjusted EBITDA measure for internal managerial evaluation purposes, as a means to evaluate period-to-period comparisons and as a performance metric for the vesting and release of certain of our performance-based equity awards. SEC Regulation G and other federal securities laws regulate the use of financial measures that are not prepared in accordance with GAAP. We believe this measure provides important supplemental information to investors. However, we do not, and you should not, rely on non-GAAP financial measures alone as measures of our performance.

Non-GAAP Revenue

The use of non-GAAP revenue allows management to evaluate, among other things, the revenue from the Company’s core businesses and trends across different reporting periods on a consistent basis, independent of special items. In addition, non-GAAP revenue is an important component of management’s internal performance measurement and incentive and reward process as it is used to assess the current and historical financial results of the business and for strategic decision making, preparing budgets, obtaining targets and forecasting future results. Management presents this non-GAAP financial measure to enable investors and analysts to evaluate the Company’s revenue generation performance relative to the direct costs of operations of ON Semiconductor’s core businesses.

Non-GAAP Gross Profit and Gross Margin

The use of non-GAAP gross profit and gross margin allows management to evaluate, among other things, the gross margin and gross profit of the Company’s core businesses and trends across different reporting periods on a consistent basis, independent of non-cash items including, generally speaking, expensing of appraised inventory fair market value step-up and non-recurring facility costs. In addition, it is an important component of management’s internal performance measurement and incentive and reward process as it is used to assess the current and historical financial results of the business and for strategic decision making, preparing budgets, obtaining targets and forecasting future results. Management presents this non-GAAP financial measure to enable investors and analysts to evaluate our revenue generation performance relative to the direct costs of revenue of ON Semiconductor’s core businesses.

Non-GAAP Operating Income and Operating Margin

The use of non-GAAP operating income and operating margin allows management to evaluate, among other things, the operating margin and operating income of the Company’s core businesses and trends across different reporting periods on a consistent basis, independent of non-cash items including, generally speaking, expensing of appraised inventory fair market value step-up, non-recurring facility costs, amortization and impairments of intangible assets, third party acquisition and divestiture related costs, restructuring charges and certain other special items as necessary. In addition, it is an important component of management’s internal performance measurement and incentive and reward process as it is used to assess the current and historical financial results of the business and for strategic decision making, preparing budgets, obtaining targets and forecasting future results. Management presents this non-GAAP financial measure to enable investors and analysts to evaluate the Company’s revenue generation performance relative to the direct costs of operations of ON Semiconductor’s core businesses.

Non-GAAP Net Income Attributable to ON Semiconductor and Non-GAAP Diluted Earnings Per Share

The use of non-GAAP net income attributable to ON Semiconductor and non-GAAP diluted earnings per share allows management to evaluate the operating results of ON Semiconductor’s core businesses and trends across different reporting periods on a consistent basis, independent of non-cash items including, generally, the amortization and impairments of intangible assets, expensing of appraised inventory fair market value step-up, non-recurring facility costs, restructuring, gains and losses on debt prepayment, non-cash interest expense, actuarial (gains) losses on pension plans and other pension benefits, third party acquisition and divestiture related costs, tax indemnification by third parties, tax impact of these items and other non-GAAP adjustments and certain other special items, as necessary. In addition, these items are important components of management’s internal performance measurement and incentive and reward process, as they are used to assess the current and historical financial results of the business and for strategic decision making, preparing budgets, setting targets and forecasting future results. Management presents these non-GAAP financial measures to enable investors and analysts to understand the results of operations of ON Semiconductor’s core businesses and, to the extent comparable, to compare our results of operations on a more consistent basis against those of other companies in our industry.

Free Cash Flow

The use of free cash flow allows management to evaluate, among other things, the ability of the Company to make interest or principal payments on its debt. Free cash flow is defined as the difference between cash flow from operating activities and capital expenditures disclosed under investing activities in the consolidated statement of cash flows. Free cash flow is not an alternate to cash flow from operating activities as a measure of liquidity. It is an important component of management’s internal performance measurement and incentive and reward process as it is used to assess the current and historical financial results of the business and for strategic decision making, preparing budgets, obtaining targets and forecasting future results. Management presents this non-GAAP financial measure to enable investors and analysts to evaluate our revenue generation performance relative to the direct costs of operations of ON Semiconductor’s core businesses.

Non-GAAP Diluted Share Count

The use of non-GAAP diluted share count allows management to evaluate, among other things, the potential dilution due to the outstanding stock options and restricted stock units excluding the dilution from the convertible notes that is covered by hedging activity up to a certain threshold. In periods when the quarterly average stock price per share exceeds $20.72, the non-GAAP diluted share count includes the anti-dilutive impact of the Company’s hedge transactions issued concurrently with the 1.625% convertible notes. As such, at an average stock price per share between $20.72 and $30.70, the hedging activity offsets the potentially dilutive effect of the 1.625% convertible notes. In periods when the quarterly average stock price per share exceeds $52.97, the non-GAAP diluted share count includes the anti-dilutive impact of the Company’s hedge transactions issued concurrently with the 0% convertible notes. As such, at an average stock price per share between $52.97 and $74.34, the hedging activity offsets the potentially dilutive effect of the 0% convertible notes.

Sarah Rockey

Corporate/Media Communications

ON Semiconductor

(602) 244-5190

[email protected]

Parag Agarwal

Vice President – Investor Relations & Corporate Development

ON Semiconductor

(602) 244-3437

[email protected]

KEYWORDS: United States North America Arizona

INDUSTRY KEYWORDS: Semiconductor Hardware Data Management Consumer Electronics Technology

MEDIA:

Logo
Logo

Selecta Biosciences to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in upcoming investor conferences in August.

Details on the panel can be found below.

  • BTIG Virtual Biotechnology Conference 2021

    Format: Fireside chat and one-on-one investor meetings
    Date: Monday, August 9, 2021
    Presentation Time: 3:00 p.m. EDT
  • Canaccord Genuity 41

    st

    Annual Growth Conference

    Format: Fireside chat and one-on-one investor meetings
    Date: Wednesday, August 11, 2021
    Presentation Time: 9:30 a.m. EDT
    Webcast: Click Here

BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative. An archived webcast of the Canaccord corporate update will be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.

Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:

Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
[email protected]

For Media: 

Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
[email protected] 



Resources Connection, Inc. Announces the Appointment of David P. White to the Board of Directors

Resources Connection, Inc. Announces the Appointment of David P. White to the Board of Directors

IRVINE, Calif.–(BUSINESS WIRE)–
Resources Connection, Inc. (Nasdaq: RGP), announced today that RGP’s Board of Directors voted to increase the size of its Board of Directors from ten to eleven members and appointed David P. White to the Board of Directors, effective as of July 29, 2021. Mr. White will also serve as a member of the Corporate Governance and Nominating Committee of the Board.

“We are delighted to welcome David White to the Board of Directors,” said Kate W. Duchene, Chief Executive Officer of RGP. “David and I practiced employment law together at O’Melveny & Myers LLP early in our professional careers so I have experienced firsthand his intellect, people skills and strategic counsel. David brings deep expertise in human capital and regulatory matters to help guide the company in the new realities of work.”

Mr. White previously served as the National Executive Director and chief negotiator of the Screen Actors Guild-American Federation of Television and Radio Artists (SAG-AFTRA) from 2009 to June 2021. In this role, Mr. White served as chief executive officer and strategist for the world’s largest entertainment union. Prior to rejoining SAG-AFTRA in 2009, where he previously served as general counsel from 2002 to 2006, Mr. White was managing principal of Los Angeles-based Entertainment Strategies Group LLC from 2006 to 2009, providing consulting services to the entertainment industry. He was also previously a labor and employment attorney at O’Melveny & Myers LLP.

Mr. White is a Rhodes Scholar and a graduate of Grinnell College, Stanford Law School and The Queen’s College, Oxford University. He currently serves as a board member of the Federal Reserve Bank of San Francisco, where he serves on the Audit and Risk Management Committee and Bank Governance Committee, as a board member of the Motion Pictures and Television Fund, where he serves on the Audit Committee, and as a board member of The Actors Fund, where he serves on the Strategic Planning Committee.Mr. White also serves as a commissioner for the Entertainment Industry Commission on Eliminating Sexual Harassment and Advancing Equality in the Workplace.

ABOUT RGP

RGP is a global consulting firm that enables rapid business outcomes by bringing together the right people to create transformative change. As a human capital partner to our global client base, we support our clients’ needs through both professional staffing and project execution in the areas of transactions, regulations, and transformations. Our pioneering approach to workforce strategy and our agile human capital model quickly align the right resources for the work at hand with speed and efficiency. Our engagements are designed to leverage human connection and collaboration to deliver practical solutions and more impactful results that power our clients’, consultants’ and partners’ success. Our mission as an employer is to connect our team members to meaningful opportunities that further their career ambitions within the context of a supportive talent community of dedicated professionals. With approximately 5,000 professionals, we annually engage with over 2,100 clients around the world from over 40 physical practice offices and multiple virtual offices. We are their partner in delivering on the future of work. Headquartered in Irvine, California, RGP is proud to have served over 85% of the Fortune 100.

The Company is listed on the Nasdaq Global Select Market, the exchange’s highest tier by listing standards. To learn more about RGP, visit: http://www.rgp.com. (RGP-F)

Media Contact:

Michael Sitrick

(US+) 1-310-788-2850

[email protected]

Investor Contact:

Jenn Ryu, Chief Financial Officer

(US+) 1-714-430-6500

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Consulting Legal Professional Services Human Resources

MEDIA:

Logo
Logo

Cerence to Announce Fiscal Third Quarter Results on August 9, 2021

BURLINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) — Cerence Inc. (NASDAQ: CRNC), AI for a world in motion, will announce its third quarter, fiscal year 2021 financial results for the quarter ended June 30, 2021, on Monday, August 9, 2021, at 7:00 a.m. EDT / 4:00 a.m. PDT.

The company will host a live conference call and webcast, with accompanying slides to discuss the results, on the same day at 10:00 a.m. Eastern Time / 7:00 a.m. Pacific Time. Interested investors and analysts are invited to dial into the conference call by using 1.844.467.7116 (domestic) or +1.409.983.9838 (international) and entering the pass code 9974299. Webcast access will be available in the Investor Information section of the company’s website at www.cerence.com.

The teleconference replay will be available through August 16, 2021. The replay dial-in number is 1.855.859.2056 (domestic) or +1.404.537.3406 (international) using pass code 9974299. The webcast replay will be available on the company’s website at www.cerence.com.

About Cerence Inc.

Cerence (NASDAQ: CRNC) is the global industry leader in creating unique, moving experiences for the mobility world. As an innovation partner to the world’s leading automakers and mobility OEMs, it is helping advance the future of connected mobility through intuitive, powerful interaction between humans and their cars, two-wheelers, and even elevators, connecting consumers’ digital lives to their daily journeys no matter where they are. Cerence’s track record is built on more than 20 years of knowledge and nearly 400 million cars shipped with Cerence technology. Whether it’s connected cars, autonomous driving, e-vehicles, or buildings, Cerence is mapping the road ahead. For more information, visit www.cerence.com.

Investor Contact Information

Rich Yerganian
Vice President of Investor Relations
Cerence Inc.
Tel: 617-987-4799
Email: [email protected]

 



STRATA Skin Sciences Announces Appointment of New VP of Marketing

HORSHAM, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Brent Cowgill as Vice President of Marketing.

“We are delighted to welcome Mr. Cowgill to the STRATA team,” said Robert J. Moccia, Chief Executive Officer of STRATA. “His extensive background in healthcare sales and marketing will prove to be invaluable in the execution of our strategic marketing efforts to both customers and dermatologists. One of our highest priorities at STRATA is driving superior commercial execution and we believe that Brent is the ideal leader to help us achieve and maintain this goal.”

Mr. Cowgill has over 20 years of healthcare sales and marketing experience. Prior to joining STRATA he managed Vantage Marketing, a healthcare consulting firm which he founded 9 years ago, that focused on commercializing prescription treatments in the U.S. market. Brent has held various commercial positions at both Fortune 500 and emerging healthcare companies. His roles and responsibilities, while varied, stayed focused on supporting the strategic and commercial efforts at companies such as Graceway Pharmaceuticals, Bioglan Pharmaceuticals, and Bristol Myers Squibb. Mr. Cowgill holds a B.S. degree in Marketing from Bowling Green State University.

“I am very excited to join the STRATA team,” said Mr. Cowgill. “I look forward to helping STRATA expand its presence within the dermatology market while building upon XTRAC’s commercial success as the market’s leading excimer laser technology used to treat several chronic skin conditions that afflict millions of people worldwide.”

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

The Company’s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.

STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

Investor Contact    
Leigh Salvo    
(415) 937-5404    
[email protected]    



Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant


Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar LifeScience, a Johnson & Johnson company

Nes Ziona, Israel, Aug. 02, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the hiring of Tzvi Palash as Project Lead to manage the design and construction of the Company’s new cGMP AllocetraTM manufacturing plant.

“Tzvi is a highly talented industry veteran, and we are thrilled that he is joining our team,” said Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex. “He has successfully led the construction of multiple manufacturing plants, with experience specifically in the cell therapy space, leaving him well suited for his new role. I look forward to working with him to increase our manufacturing capacity in preparation for upcoming clinical trials and the potential commercialization of AllocetraTM, if approved.”

Mr. Palash brings over 35 years of experience in the healthcare industry to Enlivex and has extensive expertise leading the construction of pharmaceutical manufacturing plants. Mr. Palash joins Enlivex from Gamida Cell where, as Chief Operating Officer (COO), he was responsible for overseeing operational activities including the recently completed construction of a cell therapy manufacturing plant. Prior to that, Mr. Palash was the COO of Protalix Biotherapeutics, Inc., where he led all operational activities through the approval of Elelyso®, the company’s plant cell culture-derived protein product, by the U.S. Food and Drug Administration (FDA). Prior to joining Protalix, Mr. Palash led the planning, construction, scale-up and regulatory oversight of an Israel-based manufacturing facility as a COO and General Manager at ColBar LifeScience Ltd, a biomaterials company acquired by Johnson & Johnson. He also successfully led FDA audits for Evolence® and Ossix®, and was a member of the Global Aesthetic Management Team within the Consumer Group of Johnson & Johnson. Earlier in his career, Mr. Palash held operational roles at Teva Pharmaceutical Industries and Interpham Laboratories.

Mr. Palash added, “The opportunity to lead the design and construction of Enlivex’s new manufacturing plant is truly exciting. I believe that the Company has generated compelling clinical data in sepsis and COVID-19, preclinical data in solid tumors, and Allocetra’s broadly applicable mechanism of action positions Enlivex as a future leader in cell therapies for infectious, inflammatory and oncologic diseases. I am eager to begin working with my new colleagues and believe that our complementary skill sets will serve us well as we continue to advance AllocetraTM’s development.”

ABOUT ALLOCETRA

TM

AllocetraTM is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as “unmet medical needs”, as a stand-alone therapy or in combination with leading therapeutic agents.

ABOUT
ENLIVEX

Enlivex is a clinical stage immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA

TM

 programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect
Enlivex’s
business and prospects, including the risks that
Enlivex
may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA

TM

 product line could also be affected by
a number of
other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental,
technological
and other factors discussed in
Enlivex’s
filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT

Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
[email protected]

INVESTOR RELATIONS CONTACT

Eric Ribner
LifeSci Advisors
[email protected]



DSS Continues to Grow its Healthcare Segment through $1M Investment in Vivacitas Oncology

ROCHESTER, N.Y., Aug. 02, 2021 (GLOBE NEWSWIRE) — Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets, announced today that its subsidiary, DSS Biomedical International, Inc. (“DSS Biomedical”), completed a $1 million equity investment in Vivacitas Oncology, Inc. (“Vivacitas”), a clinical-stage company focused on difficult-to-treat cancers.

“We continue to demonstrate our commitment to addressing unmet needs in human healthcare and wellness through key strategic investments,” stated Frank D. Heuszel, CEO of DSS. “With a rich pipeline of promising assets, Vivacitas provides significant upside potential.”

Vivacitas Oncology Inc. focuses on developing new treatment options to treat cancers resistant to currently available therapies. It originated in 2015 with the vision of Dr. Joseph Rubinfeld (co-founder of Amgen) and the endorsement of Infusion 51a, LP (infusion51a.com), an impact investment fund designed to create value in underappreciated companies from the Precision Medicine and BioTech industry.

Vivacitas’ lead development candidate (AR-67) is a novel lipophilic next-generation camptothecin (Topiosomerase-1 enzyme inhibitor) compound with the potential to deliver improved efficacy and tolerability, employing a proprietary synthesis method.

AR-67 has in vitro, Phase I, and Phase II data in multiple solid tumor types. For instance, it has demonstrated potential improvement in progression-free survival (6-29 months) in glioblastoma patients, while significantly reducing severe side effects usually associated with this drug class (e.g., grade 4 diarrhea).

Jeffrey Stephens, founder, CEO and director of Infusion 51a and board member of Vivacitas Oncology said, “Vivacitas Oncology is excited to work with DSS and the Impact BioMedical team as we continue to execute on our efforts to expand Vivacitas operations and develop new treatment options for cancer patients worldwide.”

About Impact BioMedical, Inc.

Impact BioMedical, Inc. (“Impact BioMedical”) is a wholly owned subsidiary of DSS and a unique technology source, developer, and business partner in addressing unmet needs in human healthcare and wellness. For more information on Impact BioMedical visit http://impbio.com/.

About Document Security Systems, Inc.

DSS is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of $25 billion.

For more information on DSS visit http://www.dsssecure.com.

Investor Contact:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected] 

About Vivacitas Oncology, Inc.

Vivacitas Oncology is a private clinical stage biopharmaceutical company focused on combating those cancers that have proven to be frustratingly resistant to current treatment modalities. It originated with the vision of Dr. Joseph Rubinfeld (co-founder of Amgen) and Infusion 51a, LP with the intent to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. Through an enduring spirit, Vivacitas continues to apply clarity, tenacity, and vision in our fight against intractable cancers and our pursuit of new treatment options for patients and their families worldwide.

For further information please visit www.vivaoncology.com or [email protected].

Safe Harbor Disclosure

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements related to the Company’s intended use of proceeds and other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property matters; competition; as well as other risks described in the section entitled “Risk Factors” in the prospectus and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.